Abstract
We have recently demonstrated that both antibodies to Galα(1,3)Gal, and the Galα(1,3)Gal binding lectin (IB4), bind a synthetic peptide (DAHWESWL), there being a similar recognition of carbohydrate and peptide structures. We now report that the anti-Galα(1,3)Gal antibodies and IB4 lectin also react with peptides encoded by mucin genes (MUC 1, 3, 4)-sequences known to be rich in serine, threonine and proline. This activity was demonstrated (1) by the ability of mucin derived peptides to block the reaction of anti-Galα(1,3)Gal antibodies and IB4 lectin with a Galα(1,3)Gal+ pig endothelial cell line; the reactions were specific and did not occur with a random peptide containing the same sequences or with other mucin peptides; (2) by the fact that anti-mucin1 antibodies could react with the Galα(1,3)Gal expressed after transfection of COS cells (Galα(1,3)Gal-, Muc1-) with cDNA encoding the pig α,3galactosyltransferase; and (3) that the IB4 lectin and anti-Galα(1,3)Gal antibodies could react with mucin 1 found on the surface of human breast cancer cells. Thus natural occurring anti-Galα(1,3)Gal antibodies found in all human serum can react with self (Muc1) peptides expressed in large amounts on the surface of tumour cells but not on normal cells. The findings are of interest and serve to explain the previously reported findings that human cells can, at times, express Galα(1,3)Gal; such expression is an artefact, the reaction is due to the phenomenon described herein, i.e. that anti-Galα(1,3)Gal antibodies react with mucin peptides. Abbreviations: HPLC, high performance liquid phase chromatography; HRP, horse radish peroxidase; mAb, monoclonal antibody; NHS, normal human serum; PBS, phosphate buffered saline; VNTR, variable number of tandem repeats
Similar content being viewed by others
References
Stacker SA, Thompson CH, Sacks NPM, Tjandra J, Lowe M, Bishop J, McKenzie IFC (1988) Cancer Res 48: 7060–6.
McKenzie I, Xing P-X (1990) Cancer Cells 2: 75–8.
Arklie J, Taylor-Papadimitriou J, Bodmer WF, Eyan M, Millis R (1981) Int J Cancer 28: 23–9.
Stacker SA, Thompson C, Riglar C, McKenzie IFC (1985) J Natl Cancer Inst 75: 801–11.
Burcell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R, Lampost D (1987) Cancer Res 47: 5476–82.
Gendler JD, Spicer AP (1995) Annu Rev Physiol 265: 607–34.
Gendler SJ, Burchell JM, Duhig T, Lamport D, White R, Parker M, Taylor-Papadimitriou J (1987) Proc Natl Acad Sci USA 84: 6060–4.
Wreschner DH, Hareuveni M, Tsarfaty I, Smorodinsky N, Horev J, Zaretsky J, Kotkes P, Weiss M, Lathe R, Dion A, Keydar I (1990) Eur J Biochem 189: 463–74.
Xing P-X, McKenzie IFC (1191) In Breast Epithelial Antigens: Molecular Biology to Clinical Applications, Ceriani RL, Ed. pp. 45–54. New York and London: Plenum Press
Xing P-X, Prenzoska J, McKenzie IFC (1992) Mol Immunol 29: 641–50.
Barnd DL, Lan MS, Metzgar RS, Finn OJ (1989) Proc Natl Acad Sci USA 86: 7159–63.
Galili U, Shohet SB, Kobrin E, Stults CLM, Macher BA (1988) J Biol Chem 263: 17755–62.
Sandrin MS, Vaughan HA, McKenzie IFC (1994) Transplant Rev 8: 134–49.
Sandrin MS, McKenzie IFC (1994) Immunol Rev 141: 169–90.
Joziasse DH, Shaper JH, Jabs EW, Shaper NC (1991) J Biol Chem 266: 6991–8.
Larsen RD, Rivera-Marrero CA, Ernst LK, Cummings RD, Lowe JB (1990) J Biol Chem 265: 7005–61.
Galili U, Macher BA, Buehler J, Shohet SB (1985) J Exp Med 162: 573–82.
Galili U (1989) Lancet 2: 358–61.
Castronova V, Colin C, Parent B, Foidart J, Lambotte R, Mahieu P (1989) J Natl Cancer Inst 81: 212–16.
Petryniak J, Varani J, Ervin PR, Goldstein IJ (1991) Cancer Lett 60: 59–65.
Vaughan HA, Oldenburg KR, Gallop MA, Atkin JD, McKenzie IFC, Sandrin MS (1996) Xenotransplantation 3: 18–23.
Xing P-X, Tjandra JJ, Stacker SA, Teh JG, Thompson CH, McLaughlin PJ, McKenzie IFC (1989) Immunol Cell Biol 67: 183–5.
Hayes CE, Goldstein IJ (1974) J Biol Chem 249: 1904–14.
McKenzie IFC, Xing P-X, Vaughan HA, Prenzoska J, Dabkowski PL, Sandrin MS (1994) Transplant Immunol 2: 81–6.
Sandrin MS, Vaughan HA, Dabkowski PL, Mckenzie IFC (1993) Proc Natl Acad Sci USA 90: 11391–5.
Merrifield RB (1963) J Am Chem Soc 85: 2149–54.
Sandrin MS, Gumley TP, Henning MM, Vaughan HA, Gonez LJ, Trapani JA, McKenzie IFC (1992) J Immunol 149: 1636–41.
Jerome KR, Bu D, Finn OJ (1992) Cancer Res 52: 5985–90.
Sandrin MS, Dabkowski PL, Henning MM, Mouhtouris E, McKenzie IFC (1994) Xenotransplantation 1: 81–8.
Vaughan HA, Henning MM, Purcell DFJ, McKenzie IFC, Sandrin MS (1991) Immunogenetics 33: 113–17.
Apostolopoulos V, Xing P-X, Trapani JA, McKenzie IFC (1993) Br J Cancer 67: 713–20.
Oldenburg KR, Loganathan D, Goldstein IJ, Schultz PG, Gallop MA (1992) Proc Natl Acad Sci USA 89: 5393–7.
Scott JK, Loganathan D, Easley RB, Gong X, Goldstein IJ, (1992) Proc Natl Acad Sci USA 89: 5398–402.
Hoess R, Brinkman U, Handel T, Pastan I (1993) Gene 128: 43–9.
Shikhman AR, Cunningham MW (1994) J Immunol 152: 4375–87.
Shikhman AR, Greenspan NS, Cunningham MW (1994) J Immunol 153: 5593–606.
Westerlink MA, Giardina PC, Apicella MA, Kieber-Emmons T (1995) Proc Natl Acad Sci USA 92: 4021–5.
Price MR, Hudecz F, O'Sullivan C, Baldwin RW, Edwards PM, Tendler SJB (1990) Mol Immunol 27: 795–802.
Xing P-X, Prenzoska J, Quelch K, McKenzie IFC (1992) Cancer Res 52: 2310–17.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sandrin, M.S., Vaughan, H.A., Xing, PX. et al. Natural human anti-Galα(1,3)Gal antibodies react with human mucin peptides. Glycoconj J 14, 97–105 (1997). https://doi.org/10.1023/A:1018521217276
Issue Date:
DOI: https://doi.org/10.1023/A:1018521217276